Startup raises over $6 million for early Alzheimer's detection AI

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

> This Story

注册记数器 to rate this News Story
Forward Printable StoryPrint Comment




Alzheimers/Neurology Homepage

Study shows 30 percent drop in unnecessary head CTs with BrainScope One May help ensure appropriate use of imaging

AI tool matches radiologist in amyloid detection for Alzheimer's Processes entire whole-brain slice with 98.7 percent accuracy

Mild combat-related brain trauma can be detected with magnetoencephalography (MEG) Superior to conventional neuroimaging techniques like MR, CT

New study shows value of 7T MR for evaluating MS progression Can detect cortical lesions better than conventional scanners

PET uncovers abnormal tau deposits associated with CTE in live subjects May enable diagnosis of CTE in living people one day

Amyloid PET scans help with Alzheimer's clinical management New insights from the 11,000 patient IDEAS study

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

APRINOIA and Celgene partner on promising PET tracer APN-1607 holds potential for visualizing tau pathology in diverse tauopathies

Opening blood brain barrier, focused ultrasound is closing therapy gap Insights from the 6th International Symposium on Focused Ultrasound

Stryker inks two partnerships for enhanced surgical guidance Offering whole-brain tractography and detail-rich imaging

Startup raises over $6 million for early Alzheimer's detection AI

Gus Iversen , Editor in Chief
With a $6.3 million round of venture capital financing completed, Altoida is planning to commercialize its FDA-cleared and CE Mark-approved Alzheimer's risk prediction medical device in the U.S. and EU.

By collecting digital biomarkers with artificial intelligence, machine learning and augmented reality, Altoida can reportedly detect Alzheimer's disease up to 10 years prior to the onset of cognitive impairment symptoms with 94 percent accuracy in patients over 61 years old.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

Altoida's app-based product analyzes visuospatial and executive function during complex activities of daily living through a battery of three tests that ask patients to hide and seek virtual objects in a physical space. The company has validated its platform and methodology in more than 12 peer-reviewed journal publications and in more than 200 independent studies.

"As the world's effort to introduce meaningful therapies for Alzheimer's disease inches closer and closer to success, it is clear that the greatest benefit will come to those whose disease is detected at a very early stage," said Dr. Jonathan L. Liss, director at Columbus Memory Center and Founder of Columbus Memory Project, who has been using Altoida's technology since September 2018, in a statement.

In 2019 alone, Alzheimer's disease and other dementias will cost the U.S. $290 billion, according to the Alzheimer's Association. By 2050, these costs could rise as high as $1.1 trillion.

Leading the Series A funding was M Ventures, the corporate venture capital arm of Merck.

Alzheimers/Neurology Homepage

You Must Be Logged In To Post A Comment